Quarterly report pursuant to Section 13 or 15(d)

License Agreements (Details)

v3.20.1
License Agreements (Details) - USD ($)
3 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Deferred revenue $ 600,000 $ 1,500,000
BioSense Global LLC [Member]    
Upfront payment 1,650,000  
Amount received from upfront payment 1,500,000  
Deferred revenue 600,000  
Amount due 150,000  
Milestone payment 84,500,000  
Zhejiang HaiChang Biotechnology Co., Ltd. [Member]    
Upfront payment 250,000  
Fixed consideration 250,000  
RX-3117 License [Member] | BioSense Global LLC [Member]    
Upfront payment 750,000  
Revenue recognized 0  
RX-3117 Material [Member] | BioSense Global LLC [Member]    
Revenue recognized 900,000  
RX-0201 [Member] | Zhejiang HaiChang Biotechnology Co., Ltd. [Member]    
Milestone payment 63,000,000  
RX-0047 [Member] | Zhejiang HaiChang Biotechnology Co., Ltd. [Member]    
Milestone payment $ 33,000,000